We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

QLYS:NASDAQQualys, Inc. Analysis

Data as of 2026-06-10 - not real-time

$109.71

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Qualys, Inc. is trading at $109.71, comfortably above its 20‑day SMA ($102.3) and 50‑day SMA ($92.99) while still below the 200‑day SMA ($118.34), indicating short‑term strength but long‑term caution. Technicals are supportive – the MACD is bullish (line > signal) and the RSI sits at 64.5, suggesting momentum without immediate overbought pressure. Fundamentals are robust: a gross margin of 83%, operating margin of 35% and ROE of 38% underscore high profitability, while a forward PE of 13.3 versus an industry average of 36 points to relative cheapness. The DCF‑derived fair value of $144.75 implies the stock is modestly undervalued, though analyst consensus (median target $96) is more conservative. Recent material news – the TotalCloud solution achieving FedRAMP High Authorization – adds a regulatory win that could expand government‑sector exposure and bolster confidence.
Despite a volatile 30‑day price swing of 50% and a beta around 0.65, the company’s strong cash position, low debt, and consistent revenue growth (~10%) provide a solid defensive cushion, supporting a buy stance for investors with medium to long horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • Positive FedRAMP High authorization news
  • Strong profit margins and cash generation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward PE of 13.3 vs industry 36 indicating value
  • High ROE (38%) and consistent revenue growth
  • Potential upside to DCF fair value of $144.75

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable high gross and operating margins
  • Expanding government and compliance market through FedRAMP
  • Strong balance sheet with ample cash and low debt

Key Metrics & Analysis

Financial Health

Revenue Growth9.80%
Profit Margin29.41%
P/E Ratio19.7
ROE37.72%
ROA13.85%
Debt/Equity9.16
P/B Ratio6.8
Op. Cash Flow$295.1M
Free Cash Flow$237.4M
Industry P/E36.0

Technical Analysis

TrendNeutral
RSI64.5
Support$84.63
Resistance$115.89
MA 20$102.30
MA 50$92.99
MA 200$118.34
MACDBullish
VolumeStable
Fear & Greed Index84.25

Valuation

Fair Value$144.75
Target Price$107.39
Upside/Downside-2.12%
GradeFair
TypeBlend

Risk Assessment

Beta0.01
Volatility50.17%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.